115.96 0.00 (0.00%)
After hours: 4:48PM EDT
|Bid||114.05 x 800|
|Ask||117.67 x 800|
|Day's Range||115.75 - 117.79|
|52 Week Range||101.42 - 142.50|
|Beta (3Y Monthly)||0.91|
|PE Ratio (TTM)||31.55|
|Earnings Date||Oct 23, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||140.93|
Francis R. Facchini, M.D., FSIR, fills new role for interventional oncology globally PALO ALTO, Calif. , Sept.16, 2019 /PRNewswire/ -- Varian (NYSE: VAR) has named Francis R. Facchini , M.D., FSIR, as ...
Company Ranked Highest in Eight Key Performance Areas and Net Promotor Score PALO ALTO, Calif. , Sept. 16, 2019 /PRNewswire/ -- Varian (NYSE: VAR) has been recognized again as a leader in the annual IMV ...
PALO ALTO, Calif. , Sept. 16, 2019 /PRNewswire/ -- Varian (NYSE: VAR) today announced its ProBeam 360° proton therapy system is now available in a multi-room configuration. The ProBeam 360° system is the ...
PALO ALTO, Calif., Sept. 15, 2019 /PRNewswire/ -- Strengthening its leadership in delivering innovative new solutions to transform cancer care globally, Varian (VAR) today announced Ethos™ therapy, an Adaptive Intelligence™ solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution designed to increase the capability, flexibility and efficiency of radiotherapy.
Netflix’s original slate dwarfs the new entrants. As the industry transitions toward a larger mix of digital transactions, we believe that Chipotle is in a leading position to establish a digital moat.
PALO ALTO, Calif. and PHILADELPHIA , Sept. 13, 2019 /PRNewswire/ -- Varian (NYSE: VAR) today announced it is investing in Oncora Medical and partnering to accelerate the development of software tools to ...
PALO ALTO, Calif. , Sept. 12, 2019 /PRNewswire/ -- Varian (NYSE: VAR) today announced its fourth quarter fiscal year 2019 earnings release date. The Company will report results for the fourth quarter of ...
PALO ALTO, Calif. and BEIJING, Sept. 11, 2019 /PRNewswire/ -- Varian (VAR) has received notice from the Customs Tariff Commission of the State Council of China that medical linear accelerators are excluded from the additional tariffs China imposed on US products that began on August 23, 2018. "We are grateful for the China government's determination to fight cancer and its recognition of the positive impact of radiotherapy treatments," said Dow Wilson, president and chief executive officer, Varian. "Varian envisions a world without fear of cancer, and we are committed to empowering our users to achieve new victories against cancer with our cancer care solutions.
PALO ALTO, Calif. , Sept. 10, 2019 /PRNewswire/ -- The New York Proton Center (NYPC) has treated its first proton therapy cancer patients. Equipped with the Varian ProBeam ® proton therapy system, NYPC ...
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...
Stryker, Varian Medical Systems and Becton, Dickinson & Co. could feel pressure after China targeted medical products in another round of tariffs on imports, an analyst said Thursday.
PALO ALTO, Calif. , Aug. 28, 2019 /PRNewswire/ -- Varian (NYSE: VAR) has completed the installation of the cyclotron for its ProBeam ® Compact single-room proton therapy system at Sylvester Comprehensive ...
Today we are going to look at Varian Medical Systems, Inc. (NYSE:VAR) to see whether it might be an attractive...
PALO ALTO, Calif., Aug. 21, 2019 /PRNewswire/ -- Varian (VAR) today announced that Phil Febbo, MD, chief medical officer (CMO) at Illumina has been appointed to the Varian Board of Directors, effective August 16, 2019. "We are proud to have Phil Febbo join the Varian Board," said R. Andrew Eckert, chairman of Varian's Board of Directors. "Phil has a strong background in both clinical and research work, as well as company strategy.
PALO ALTO, Calif. , Aug. 21, 2019 /PRNewswire/ -- Varian (NYSE: VAR) today announced it has successfully completed its asset purchase of the Boston Scientific portfolio of drug-loadable microsphere and ...
PALO ALTO, Calif., Aug. 19, 2019 /PRNewswire/ -- Varian (VAR) today announced that its executive management team will be hosting an Investor Day on Friday, November 15, 2019 at The Plaza Hotel, Fifth Avenue at Central Park South, New York, NY 10019, from 8:00am to 1:00pm ET. Varian will outline its growth initiatives in radiation oncology, interventional oncology, and more broadly across cancer care driven by its 'Intelligent Cancer Care' approach, the next wave of progress in oncology that harnesses advanced technologies like artificial intelligence, machine learning, and data analytics to ensure coordination and connectivity at every point of care. 'Intelligent Cancer Care' puts the patient and provider at the center of our thinking to help realize our vision of a world without fear of cancer.